PALI-1908 / Palisade Bio, GiiAnt Pharma - LARVOL DELTA

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire) - "Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end....Additionally, the Company’s platform technology provides the opportunity to expand its pipeline across immune, inflammatory and fibrotic disease, including its PALI-1908 program in preclinical development for fibro stenotic Crohn’s Disease, which shares multiple synergies with the lead PALI-2108 program."

Clinical • New P1 trial • Crohn's disease • Immunology • Inflammatory Bowel Disease